# Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Source: https://onco.cc/trials/nct07627711/  
OnCo record `nct07627711` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine, Cyclophosphamide in pancreatic ductal adenocarcinoma, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma is a phase 1/2 interventional study registered as NCT07627711 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy). Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07627711
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Biomarker-guided, Dose-escalation and Expansion Study of Dual-targeting CAR-NK Cells Directed Against Mesothelin (MSLN) and MUC1, With an Exploratory CLDN18.2/MUC1 Dual-target Cohort, in Patients With Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Sponsor: Beijing Biotech
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07627711: https://clinicaltrials.gov/study/NCT07627711

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07627711.json